ARTICLE | Product Development
Viking continues push for VK2735 as best in class in obesity
Dual GIP/GLP-1 agonist shows highly competitive efficacy, safety, dosing flexibility; although oral dose could limit commercial supply
November 5, 2024 12:00 AM UTC
Viking further builds the case that VK2735 could be a best-in-class GIP/GLP-1 dual agonist with additional Phase II data confirming an attractive safety profile and potential for once-monthly subcutaneous dosing.
The biotech also reported more Phase I data from an oral formulation of VK2735 that showed highly competitive efficacy, but at such a high dose that it may not be commercially viable from a manufacturing perspective...
BCIQ Company Profiles